Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Artificial Intelligence | Review

Translational precision medicine: an industry perspective

Authors: Dominik Hartl, Valeria de Luca, Anna Kostikova, Jason Laramie, Scott Kennedy, Enrico Ferrero, Richard Siegel, Martin Fink, Sohail Ahmed, John Millholland, Alexander Schuhmacher, Markus Hinder, Luca Piali, Adrian Roth

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.
Literature
1.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203–14.PubMedCrossRef
2.
Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discovery. 2014;13(6):419–31.PubMedCrossRef
3.
Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov. 2018;17(3):183–96.PubMedCrossRef
4.
5.
Feldman AM. Bench-to-bedside; clinical and translational research; personalized medicine; precision medicine-what’s in a name? Clin Transl Sci. 2015;8(3):171–3.PubMedPubMedCentralCrossRef
6.
Hey SP, Gerlach CV, Dunlap G, Prasad V, Kesselheim AS. The evidence landscape in precision medicine. Sci Transl Med. 2020;12(540):eaaw7745.PubMedCrossRef
7.
Zeggini E, Gloyn AL, Barton AC, Wain LV. Translational genomics and precision medicine: moving from the lab to the clinic. Science. 2019;365(6460):1409–13.PubMedCrossRef
8.
9.
10.
Tageja N. Bridging the translation gap - new hopes, new challenges. Fund Clin Pharmacol. 2011;25(2):163–71.CrossRef
11.
12.
Shahzad A, Don G, Cohrs RJ. Translational medicine definition by the European Society for Translational Medicine. New Horiz Transl Med. 2015;2(3):89–91.PubMedPubMedCentral
13.
Shakhnovich V. It’s time to reverse our thinking: the reverse translation research paradigm. Cts-Clin Transl Sci. 2018;11(2):98–9.CrossRef
14.
Shih HP, Zhang X, Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov. 2018;17(1):78.PubMedCrossRef
15.
Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2(7):566–80.PubMedCrossRef
16.
Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immun. 2019;144(1):1–12.PubMedCrossRef
17.
Dean K, Niven R. Asthma phenotypes and endotypes: implications for personalised therapy. BioDrugs. 2017;31(5):393–408.PubMedCrossRef
18.
Ricker CA, Crawford K, Matlock K, Lathara M, Seguin B, Rudzinski ER, et al. Defining an embryonal rhabdomyosarcoma endotype. Cold Spring Harb Mol Case Stud. 2020;6(2):a005066.PubMedPubMedCentralCrossRef
19.
20.
Shah NH, Tenenbaum JD. The coming age of data-driven medicine: translational bioinformatics’ next frontier. J Am Med Inform Assn. 2012;19(E1):E2–4.CrossRef
21.
Mayo CS, Deasy JO, Chera BS, Freymann J, Kirby JS, Hardenberg PH. How can we effect culture change toward data-driven medicine? Int J Radiat Oncol. 2016;95(3):916–21.CrossRef
22.
23.
24.
Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19(9):581–90.PubMedCrossRef
25.
Li R, Chen Y, Ritchie MD, Moore JH. Electronic health records and polygenic risk scores for predicting disease risk. Nat Rev Genet. 2020;21(8):493–502.PubMedCrossRef
26.
Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1(9):683–95.PubMedCrossRef
27.
Dupree EJ, Jayathirtha M, Yorkey H, Mihasan M, Petre BA, Darie CC. A critical review of bottom-up proteomics: the good, the bad, and the future of this field. Proteomes. 2020;8(3):14.PubMedPubMedCentralCrossRef
28.
Lamb JR, Jennings LL, Gudmundsdottir V, Gudnason V, Emilsson V. It’s in our blood: a glimpse of personalized medicine. Trends Mol Med. 2020;27(1):20–30.PubMedCrossRef
29.
Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol. 2012;29(5):543–9.PubMedCrossRef
30.
Jacob J, Ngo D, Finkel N, Pitts R, Gleim S, Benson MD, et al. Application of large-scale aptamer-based proteomic profiling to planned myocardial infarctions. Circulation. 2018;137(12):1270–7.PubMedCrossRef
31.
Gudmundsdottir V, Zaghlool SB, Emilsson V, Aspelund T, Ilkov M, Gudmundsson EF, et al. Circulating protein signatures and causal candidates for type 2 diabetes. Diabetes. 2020;69(8):1843–53.PubMedPubMedCentralCrossRef
32.
Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361(6404):769–73.PubMedPubMedCentralCrossRef
33.
Emilsson V, Gudnason V, Jennings LL. Predicting health and life span with the deep plasma proteome. Nat Med. 2019;25(12):1815–6.PubMedCrossRef
34.
35.
36.
37.
Cowen L, Ideker T, Raphael BJ, Sharan R. Network propagation: a universal amplifier of genetic associations. Nat Rev Genet. 2017;18(9):551–62.PubMedCrossRef
38.
39.
Forst CV. Network genomics–a novel approach for the analysis of biological systems in the post-genomic era. Mol Biol Rep. 2002;29(3):265–80.PubMedCrossRef
40.
Goh WW, Lee YH, Chung M, Wong L. How advancement in biological network analysis methods empowers proteomics. Proteomics. 2012;12(4–5):550–63.PubMedCrossRef
41.
Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505–21.PubMedPubMedCentralCrossRef
42.
Ruiz-Godoy L, Enriquez-Carcamo V, Suarez-Roa L, Lopez-Castro ML, Santamaria A, Orozco-Morales M, et al. Identification of specific pre-analytical quality control markers in plasma and serum samples. Anal Methods-Uk. 2019;11(17):2259–71.CrossRef
43.
Papiez A, Marczyk M, Polanska J, Polanski A. BatchI: Batch effect Identification in high-throughput screening data using a dynamic programming algorithm. Bioinformatics. 2019;35(11):1885–92.PubMedCrossRef
44.
45.
Elefsinioti A, Bellaire T, Wang A, Quast K, Seidel H, Braxenthaler M, et al. Key factors for successful data integration in biomarker research. Nat Rev Drug Discov. 2016;15(6):369–70.PubMedCrossRef
46.
Hu YJ, An Q, Sheu K, Trejo B, Fan SX, Guo Y. Single cell multi-omics technology: methodology and application. Front Cell Dev Biol. 2018;6:93–102.CrossRef
47.
Verheijen M, Tong WD, Shi LM, Gant TW, Seligman B, Caiment F. Towards the development of an omics data analysis framework. Regul Toxicol Pharm. 2020;112:104621.CrossRef
48.
Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14(6):354–62.PubMedCrossRef
49.
50.
Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3:160018.PubMedPubMedCentralCrossRef
51.
52.
Roberts SF, Fischhoff MA, Sakowski SA, Feldman EL. Perspective: transforming science into medicine: how clinician-scientists can build bridges across research’s “Valley of Death.” Acad Med. 2012;87(3):266–70.PubMedCrossRef
53.
Akhtar A. The flaws and human harms of animal experimentation. Camb Q Healthc Ethic. 2015;24(4):407–19.CrossRef
54.
Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care? J Transl Med. 2019;17(1):114.PubMedPubMedCentralCrossRef
55.
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: Development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol. 2007;34(3):607–15.PubMed
56.
57.
58.
59.
Williams SA, Slavin DE, Wagner JA, Webster CJ. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discov. 2006;5(11):897–902.PubMedCrossRef
60.
Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–93.PubMedCrossRef
61.
62.
63.
Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-guided non-adaptive trial designs in phase II and phase III: a methodological review. J Pers Med. 2017;7(1):1.PubMedCentralCrossRef
64.
Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.PubMedPubMedCentralCrossRef
65.
66.
Ivison S, Des Rosiers C, Lesage S, Rioux JD, Levings MK. Biomarker-guided stratification of autoimmune patients for biologic therapy. Curr Opin Immunol. 2017;49:56–63.PubMedCrossRef
67.
Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol. 2014;11(2):81–90.PubMedCrossRef
68.
69.
Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. The master observational trial: a new class of master protocol to advance precision medicine. Cell. 2020;180(1):9–14.PubMedCrossRef
70.
Kalaitzopoulos D. The potential of precision medicine. New Horiz Transl Med. 2016;3(2):63–5.
71.
Mullard A. $215 million precision-medicine initiative takes shape. Nat Rev Drug Disc. 2015;14(3):155.
72.
73.
Doble B, Tan M, Harris A, Lorgelly P. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Rev Mol Diagn. 2015;15(2):235–54.PubMedCrossRef
74.
Jorgensen JT. Companion diagnostics: the key to personalized medicine. Expert Rev Mol Diagn. 2015;15(2):153–6.PubMedCrossRef
75.
76.
Hersom M, Jorgensen JT. Companion and complementary diagnostics-focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer. Ther Drug Monit. 2018;40(1):9–16.PubMedCrossRef
77.
Lin E, Chien J, Ong FS, Fan JB. Challenges and opportunities for next-generation sequencing in companion diagnostics. Expert Rev Mol Diagn. 2015;15(2):193–209.PubMedCrossRef
78.
Tsourounis M, Stuart J, Pignato W, Toscani M, Barone J. Current trends in personalized medicine and companion diagnostics: a summary from the DIA meeting on personalized medicine and companion diagnostics. Ther Innov Regul Sci. 2015;49(4):530–43.PubMedCrossRef
79.
80.
Mansfield EA. FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res. 2014;20(6):1453–7.PubMedCrossRef
81.
82.
Milne CP, Bryan C, Garafalo S, McKiernan M. Complementary versus companion diagnostics: apples and oranges? Biomark Med. 2015;9(1):25–34.PubMedCrossRef
83.
Jorgensen JT. Companion and complementary diagnostics: clinical and regulatory perspectives. Trends Cancer. 2016;2(12):706–12.PubMedCrossRef
84.
Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, et al. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proc Natl Acad Sci USA. 2020;117(22):12288–94.PubMedCrossRefPubMedCentral
85.
Koido M, Kawakami E, Fukumura J, Noguchi Y, Ohori M, Nio Y, et al. Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nat Med. 2020;26(10):1541–8.PubMedCrossRefPubMedCentral
86.
Love-Koh J, Peel A, Rejon-Parrilla JC, Ennis K, Lovett R, Manca A, et al. The future of precision medicine: potential impacts for health technology assessment. Pharmacoeconomics. 2018;36(12):1439–51.PubMedPubMedCentralCrossRef
87.
88.
Pettitt D, Smith J, Meadows N, Arshad Z, Schuh A, DiGiusto D, et al. Regulatory barriers to the advancement of precision medicine. Expert Rev Precis Me. 2016;1(3):319–29.
89.
Vicini P, Gastonguay MR, Foster DM. Model-based approaches to biomarker discovery and evaluation: a multidisciplinary integrated review. Crit Rev Biomed Eng. 2002;30(4–6):379–418.PubMed
90.
91.
Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979;25(3):358–71.PubMedCrossRef
92.
Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship Clin Pharmacokinet. 1986;11(6):483–504.PubMed
93.
Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.PubMedCrossRef
94.
Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, et al. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. Eur J Pharm Sci. 2017;96:626–42.PubMedCrossRef
95.
Krauss M, Mueller C, Schlender J, Schuppert A, Block M, Kuepfer L. A systems pharmacology approach for translational learning and pharmakokinetic predictions across patient populations. J Pharmacokinet Phar. 2016;43:S67–8.
96.
97.
Workgroup EM, Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacomet Syst Pharmacol. 2016;5(3):93–122.CrossRef
98.
Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I. Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther. 2019;105(4):899–911.PubMedCrossRef
99.
Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773–80.PubMedCrossRef
100.
Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.PubMedPubMedCentralCrossRef
101.
Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77.PubMedPubMedCentralCrossRef
102.
Ferrero E, Dunham I, Sanseau P. In silico prediction of novel therapeutic targets using gene-disease association data. J Transl Med. 2017;15:1–6.CrossRef
103.
Rouillard AD, Hurle MR, Agarwal P. Systematic interrogation of diverse Omic data reveals interpretable, robust, and generalizable transcriptomic features of clinically successful therapeutic targets. Plos Comput Biol. 2018;14(5):e1006142.PubMedPubMedCentralCrossRef
104.
Patel-Murray NL, Adam M, Huynh N, Wassie BT, Milani P, Fraenkel E. A multi-omics interpretable machine learning model reveals modes of action of small molecules. Sci Rep. 2020;10(1):954.PubMedPubMedCentralCrossRef
105.
Swan AL, Mobasheri A, Allaway D, Liddell S, Bacardit J. Application of machine learning to proteomics data: classification and biomarker identification in postgenomics biology. OMICS. 2013;17(12):595–610.PubMedPubMedCentralCrossRef
106.
Bravo-Merodio L, Williams JA, Gkoutos GV, Acharjee A. Omics biomarker identification pipeline for translational medicine. J Transl Med. 2019;17(1):155.PubMedPubMedCentralCrossRef
107.
Sharifi-Noghabi H, Zolotareva O, Collins CC, Ester M. MOLI: multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics. 2019;35(14):i501–9.PubMedPubMedCentralCrossRef
108.
Exarchos KP, Beltsiou M, Votti CA, Kostikas K. Artificial intelligence techniques in asthma: a systematic review and critical appraisal of the existing literature. Eur Respir J. 2020;56(3):2000521.PubMedCrossRef
109.
Zhang H, Deng K, Li H, Albin RL, Guan Y. Deep learning identifies digital biomarkers for self-reported Parkinson’s disease. Patterns. 2020;1(3):100042.PubMedPubMedCentralCrossRef
110.
Guthrie NL, Carpenter J, Edwards KL, Appelbaum KJ, Dey S, Eisenberg DM, et al. Emergence of digital biomarkers to predict and modify treatment efficacy: machine learning study. Bmj Open. 2019;9(7):e030710.PubMedPubMedCentralCrossRef
111.
Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA Jr, et al. Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov. 2020;19(5):353–64.PubMedCrossRef
112.
Schuhmacher A, Gatto A, Hinder M, Kuss M, Gassmann O. The upside of being a digital pharma player. Drug Discov Today. 2020;25(9):1569–74.PubMedCrossRef
113.
Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16(11):703–15.PubMedPubMedCentralCrossRef
114.
Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: opportunities and challenges. Cancer Lett. 2020;471:61–71.PubMedCrossRef
115.
Subramanian M, Wojtusciszyn A, Favre L, Boughorbel S, Shan J, Letaief KB, et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management. J Transl Med. 2020;18(1):472.PubMedPubMedCentralCrossRef
116.
Benjamens S, Dhunnoo P, Mesko B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. Npj Digit Med. 2020;3:118.PubMedPubMedCentralCrossRef
117.
118.
Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of deep learning in biomedicine. Mol Pharm. 2016;13(5):1445–54.PubMedCrossRef
119.
Perry B, Herrington W, Goldsack JC, Grandinetti CA, Vasisht KP, Landray MJ, et al. Use of mobile devices to measure outcomes in clinical research, 2010–2016: a systematic literature review. Digit Biomark. 2018;2(1):11–30.PubMedPubMedCentralCrossRef
120.
Bakker JP, Goldsack JC, Clarke M, Coravos A, Geoghegan C, Godfrey A, et al. A systematic review of feasibility studies promoting the use of mobile technologies in clinical research. NPJ Digit Med. 2019;2(1):47.PubMedPubMedCentralCrossRef
121.
122.
Arnerić SP, Cedarbaum JM, Khozin S, Papapetropoulos S, Hill DL, Ropacki M, et al. Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem. Nat Rev Drug Discov. 2017;16(10):736.PubMedCrossRef
123.
124.
125.
126.
Dodge HH, Zhu J, Mattek NC, Austin D, Kornfeld J, Kaye JA. Use of high-frequency in-home monitoring data may reduce sample sizes needed in clinical trials. PLoS ONE. 2015;10(9):e0138095.PubMedPubMedCentralCrossRef
127.
128.
Khozin S, Coravos A. Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations. Clin Pharmacol Therapeutics. 2019;106:25–7.CrossRef
129.
Rodarte C. Pharmaceutical perspective: how digital biomarkers and contextual data will enable therapeutic environments. Digit Biomark. 2017;1(1):73–81.PubMedPubMedCentralCrossRef
130.
Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The First Frontier: Digital Biomarkers for Neurodegenerative Disorders. Digit Biomark. 2017;1(1):6–13.PubMedPubMedCentralCrossRef
131.
Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson’s disease clinical trial. Mov Disord. 2018;33(8):1287–97.PubMedPubMedCentralCrossRef
132.
Zhan A, Mohan S, Tarolli C, Schneider RB, Adams JL, Sharma S, et al. Using smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score. JAMA Neurol. 2018;75(7):876–80.PubMedPubMedCentralCrossRef
133.
Sieberts SK, Schaff J, Duda M, Pataki BÁ, Sun M, Snyder P, et al. Crowdsourcing digital health measures to predict Parkinson’s disease severity: the Parkinson’s Disease Digital Biomarker DREAM Challenge. bioRxiv. 2020;4(1):53.
134.
Ritchie K, Carriere I, Su L, O’Brien JT, Lovestone S, Wells K, et al. The midlife cognitive profiles of adults at high risk of late-onset Alzheimer’s disease: The PREVENT study. Alzheimers Dement. 2017;13(10):1089–97.PubMedCrossRef
135.
Kourtis LC, Regele OB, Wright JM, Jones GB. Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity. NPJ Dig Med. 2019;2(1):9.CrossRef
136.
Andrzejewski KL, Dowling AV, Stamler D, Felong TJ, Harris DA, Wong C, et al. Wearable sensors in Huntington disease: a pilot study. J Huntington’s Dis. 2016;5(2):199–206.CrossRef
137.
Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling AV, Fitzer-Attas C, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ Digit Med. 2020;3(1):55.PubMedPubMedCentralCrossRef
138.
139.
140.
Cerreta F, Ritzhaupt A, Metcalfe T, Askin S, Duarte J, Berntgen M, et al. Digital technologies for medicines: shaping a framework for success. Nat Rev Drug Discov. 2020;19:573–4.PubMedCrossRef
141.
Kruizinga MD, Stuurman FE, Exadaktylos V, Doll RJ, Stephenson DT, Groeneveld GJ, et al. Development of novel, value-based, digital endpoints for clinical trials: a structured approach toward fit-for-purpose validation. Pharmacol Rev. 2020;72(4):899–909.PubMedCrossRef
142.
143.
144.
145.
146.
147.
Insel TR. Digital phenotyping: technology for a new science of behavior. JAMA. 2017;318(13):1215–6.PubMedCrossRef
148.
Huckvale K, Venkatesh S, Christensen H. Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety. NPJ Digit Med. 2019;2(1):88.PubMedPubMedCentralCrossRef
149.
150.
Geissler J, Ryll B, di Priolo SL, Uhlenhopp M. Improving patient involvement in medicines research and development: a practical roadmap. Ther Innov Regul Sci. 2017;51(5):612–9.PubMedCrossRef
151.
Haerry D, Landgraf C, Warner K, Hunter A, Klingmann I, May M, et al. EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes. Front Med. 2018;5:230.CrossRef
152.
Mavris M, Furia Helms A, Bere N. Engaging patients in medicines regulation: a tale of two agencies. Nat Rev Drug Discov. 2019;18(12):885–6.PubMedCrossRef
153.
Crocker JC, Ricci-Cabello I, Parker A, Hirst JA, Chant A, Petit-Zeman S, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ. 2018;363:k4738.PubMedPubMedCentralCrossRef
154.
Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929–39.PubMedPubMedCentralCrossRef
155.
Getz K. Reflections on the evolution of patient engagement in drug development. Pharmaceut Med. 2019;33(3):179–85.PubMed
156.
157.
Boutin M, Dewulf L, Hoos A, Geissler J, Todaro V, Schneider RF, et al. Culture and process change as a priority for patient engagement in medicines development. Ther Innov Regul Sci. 2017;51(1):29–38.PubMedCrossRef
158.
Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gulmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383(9912):156–65.PubMedCrossRef
159.
160.
Maccarthy J, Guerin S, Wilson AG, Dorris ER. Facilitating public and patient involvement in basic and preclinical health research. PLoS ONE. 2019;14(5):e0216600.PubMedPubMedCentralCrossRef
161.
Chawla NV, Davis DA. Bringing big data to personalized healthcare: a patient-centered framework. J Gen Intern Med. 2013;28(Suppl 3):S660–5.PubMedCrossRef
162.
163.
Garg S, Williams NL, Ip A, Dicker AP. Clinical integration of digital solutions in health care: an overview of the current landscape of digital technologies in cancer care. JCO Clin Cancer Inform. 2018;2:1–9.PubMedCrossRef
164.
Dinh-Le C, Chuang R, Chokshi S, Mann D. Wearable health technology and electronic health record integration: scoping review and future directions. JMIR Mhealth Uhealth. 2019;7(9):e12861.PubMedPubMedCentralCrossRef
165.
166.
Khoury MJ, Bowen MS, Clyne M, Dotson WD, Gwinn ML, Green RF, et al. From public health genomics to precision public health: a 20-year journey. Genet Med. 2018;20(6):574–82.PubMedCrossRef
167.
Robertson AS, Malone H, Bisordi F, Fitton H, Garner C, Holdsworth S, et al. Cloud-based data systems in drug regulation: an industry perspective. Nat Rev Drug Discov. 2020;19(6):365–6.PubMedCrossRef
168.
Khozin S, Pazdur R, Shah A. INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology. Nat Rev Drug Discovery. 2018;17(8):529–30.PubMedCrossRef
169.
170.
171.
Shi J, Xiao Y, Zhang Y, Geng D, Cong D, Shi KX, et al. Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs. Br J Clin Pharmacol. 2020;87(5):2170–85.PubMedCrossRef
172.
173.
Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183(6):1479–95.PubMedPubMedCentralCrossRef
174.
Barh D, Tiwari S, Weener ME, Azevedo V, Goes-Neto A, Gromiha MM, et al. Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19. Comput Biol Med. 2020;126:104051.PubMedPubMedCentralCrossRef
175.
176.
Whetton AD, Preston GW, Abubeker S, Geifman N. Proteomics and informatics for understanding phases and identifying biomarkers in COVID-19 disease. J Proteome Res. 2020;19(11):4219–32.PubMedPubMedCentralCrossRef
177.
Zhang K, Liu X, Shen J, Li Z, Sang Y, Wu X, et al. Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID-19 Pneumonia using computed tomography. Cell. 2020;181(6):1423–33.PubMedPubMedCentralCrossRef
178.
Jin C, Chen W, Cao Y, Xu Z, Tan Z, Zhang X, et al. Development and evaluation of an artificial intelligence system for COVID-19 diagnosis. Nat Commun. 2020;11(1):5088.PubMedPubMedCentralCrossRef
179.
180.
Wong CK, Ho DTY, Tam AR, Zhou M, Lau YM, Tang MOY, et al. Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial. Bmj Open. 2020;10(7):e038555.PubMedPubMedCentralCrossRef
181.
182.
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99.PubMedCrossRef
183.
Cavazzana M, Bushman FD, Miccio A, Andre-Schmutz I, Six E. Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat Rev Drug Discov. 2019;18(6):447–62.PubMedCrossRef
184.
185.
Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101–14.PubMedCrossRef
186.
Sahin U, Kariko K, Tureci O. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80.PubMedCrossRef
187.
188.
Berkers G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, et al. Rectal organoids enable personalized treatment of cystic fibrosis. Cell Rep. 2019;26(7):1701–8.PubMedCrossRef
Metadata
Title
Translational precision medicine: an industry perspective
Authors
Dominik Hartl
Valeria de Luca
Anna Kostikova
Jason Laramie
Scott Kennedy
Enrico Ferrero
Richard Siegel
Martin Fink
Sohail Ahmed
John Millholland
Alexander Schuhmacher
Markus Hinder
Luca Piali
Adrian Roth
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02910-6

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue

Review

Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target

Research

Multi-parametric MRI phenotype with trustworthy machine learning for differentiating CNS demyelinating diseases

Research

Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice

Correction

Correction to: Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts

Research

Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection

Letter to the Editor

Enjoy your journey: the bergamot polyphenols from the tree to the cell metabolism
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits